Health Economics›Colorectal cancer›Advanced or metastatic disease second-line therapy

Advanced or metastatic disease second-line therapy

Colorectal cancer · 18 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 10 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
FOLFIRI and Ziv-aflibercept Variant #01	—	R 547 571	14d	6.9 mo	13.5 mo	2	R 1 095 143 PFS proxy	2
FOLFIRI and Ramucirumab Variant #01	—	R 51 232	14d	—	13.3 mo	2	R 102 465 PFS proxy	1
CAPIRI-Bev Variant #01	—	R 18 904	21d	—	16.8 mo	6	R 113 421 PFS proxy	1
FOLFIRI and Bevacizumab Variant #01	—	R 14 447	14d	6.8 mo	13.3 mo	2	R 28 895 PFS proxy	3
mFOLFOX6-B Variant #01	—	R 13 521	14d	6.8 mo	—	2	R 27 041 PFS proxy	1
FOLFIRI and Bevacizumab (L-Leucovorin) Variant #01 Partial	—	R 12 900	14d	6.1 mo	15.4 mo	2	R 25 799 PFS proxy	2
CapeOx and Erlotinib Variant #01	—	R 12 790	21d	—	—	~2	~R 25 581 indirect	—
FOLFIRI Variant #05	—	R 11 525	14d	5.0 mo	12.1 mo	2	R 23 051 PFS proxy	8
FULV Variant #29	—	R 3 601	14d	~6.2 mo	~13.2 mo	~2	~R 7 201 PFS proxy · indirect	6
CAPIRI Variant #05	—	R 2 849	21d	—	16.8 mo	9	R 25 642 PFS proxy	1
IROX Variant #01	—	R 2 774	21d	—	13.4 mo	2	R 5 548 PFS proxy	1
Irinotecan monotherapy Variant #01	—	R 2 716	42d	—	10.9 mo	11	R 29 874 PFS proxy	4
CapeOx Variant #01	—	R 2 620	21d	4.7 mo	—	9	R 21 997 PFS proxy	1
mFOLFOX6 Variant #02	—	R 2 617	14d	5.0 mo	—	12	R 31 399 PFS proxy	1
FOLFOX4 Variant #01	—	R 2 374	14d	4.8 mo	11.9 mo	3	R 7 122 PFS proxy	4
FOLFIRI (L-Leucovorin) Variant #01 Partial	—	R 2 297	14d	—	15.4 mo	2	R 4 595 PFS proxy	1
IRI-S Variant #01 Partial	—	R 1 811	28d	5.8 mo	—	2	R 3 621 PFS proxy	1
Fluorouracil monotherapy Variant #01	—	R 647	28d	—	8.5 mo	2	R 1 294 PFS proxy	—

18 of 18 regimens shown